Search Results - "ZEEUW, DICK DE"

GFR Decline as an End Point for Clinical Trials in CKD: A Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration by Levey, Andrew S., MD, Inker, Lesley A., MD, MS, Matsushita, Kunihiro, MD, PhD, Greene, Tom, PhD, Willis, Kerry, PhD, Lewis, Edmund, MD, de Zeeuw, Dick, MD, PhD, Cheung, Alfred K., MD, Coresh, Josef, MD, PhD

“…The US Food and Drug Administration currently accepts halving of glomerular filtration rate (GFR), assessed as doubling of serum creatinine level, as a…”
Get full text

Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial by Neal, Bruce, PhD, Perkovic, Vlado, PhD, de Zeeuw, Dick, PhD, Mahaffey, Kenneth W., MD, Fulcher, Greg, MD, Stein, Peter, MD, Desai, Mehul, MD, Shaw, Wayne, DSL, Jiang, Joel, PhD, Vercruysse, Frank, MD, Meininger, Gary, MD, Matthews, David, DPhil

“…Sodium glucose co-transporter 2 inhibition is a novel mode of treatment for type 2 diabetes mellitus (T2DM). The sodium glucose co-transporter 2 inhibitor…”
Get full text

Relative Incidence of ESRD Versus Cardiovascular Mortality in Proteinuric Type 2 Diabetes and Nephropathy: Results From the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) Database by Packham, David K., MD, Alves, Tahira P., MD, Dwyer, Jamie P., MD, Atkins, Robert, MBBS, DSc, de Zeeuw, Dick, MD, PhD, Cooper, Mark, MD, Shahinfar, Shahnaz, MD, Lewis, Julia B., MD, Lambers Heerspink, Hiddo J., PharmD, PhD

“…Background Previous studies have shown that patients with chronic kidney disease, including those with diabetic nephropathy, are more likely to die of…”
Get full text

Albuminuria, Estimated GFR, Traditional Risk Factors, and Incident Cardiovascular Disease: The PREVEND (Prevention of Renal and Vascular Endstage Disease) Study by Smink, Paul A., MD, Lambers Heerspink, Hiddo J., PharmD, PhD, Gansevoort, Ron T., MD, PhD, de Jong, Paul E., MD, PhD, Hillege, Hans L., MD, PhD, Bakker, Stephan J.L., MD, PhD, de Zeeuw, Dick, MD, PhD

“…Background Abnormal levels of both albuminuria and estimated glomerular filtration rate (eGFR) have been reported separately to be associated with…”
Get full text

A Prospective Cohort Study in Patients with Type 2 Diabetes Mellitus for Validation of Biomarkers (PROVALID) – Study Design and Baseline Characteristics by Eder, Susanne, Leierer, Johannes, Kerschbaum, Julia, Rosivall, Laszlo, Wiecek, Andrzej, de Zeeuw, Dick, Mark, Patrick B., Heinze, Georg, Rossing, Peter, Heerspink, Hiddo L., Mayer, Gert

“…Background/Aims: The prevalence of diabetes mellitus type 2 and kidney disease in these patients varies widely between European countries. Methods: In addition…”
Get full text

A novel drug response score more accurately predicts renoprotective drug effects than existing renal risk scores by Idzerda, Nienke M. A., Tye, Sok Cin, Zeeuw, Dick de, Heerspink, Hiddo J. L.

“…Background: Risk factor-based equations are used to predict risk of kidney disease progression in patients with type 2 diabetes order to guide treatment…”
Get full text

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes by Neal, Bruce, Perkovic, Vlado, Mahaffey, Kenneth W, de Zeeuw, Dick, Fulcher, Greg, Erondu, Ngozi, Shaw, Wayne, Law, Gordon, Desai, Mehul, Matthews, David R

“…In this report of two randomized trials, patients with type 2 diabetes at risk for cardiovascular disease received the sodium–glucose cotransporter 2 inhibitor…”
Get full text

Albuminuria: A Target for Treatment of Type 2 Diabetic Nephropathy by de Zeeuw, Dick, MD, PhD

“…Summary Both renal and cardiovascular morbidity and mortality is increased markedly in patients with type 2 diabetes. Besides the classic risk factors and…”
Get full text

Urinary Albumin Excretion and Its Relation With C-Reactive Protein and the Metabolic Syndrome in the Prediction of Type 2 Diabetes by Brantsma, Auke H, Bakker, Stephan J.L, Hillege, Hans L, Zeeuw, Dick de, Jong, Paul E. de, Gansevoort, Ronald T

“…OBJECTIVE:--To investigate urinary albumin excretion (UAE) and its relation with C-reactive protein (CRP) and the metabolic syndrome in the prediction of the…”
Get full text

Albuminuria: A Great Risk Marker, but an Underestimated Target in Diabetes by de Zeeuw, Dick, Raz, Itamar

“…The current approach of patients with diabetes is first to assess their risk profile by measuring risk factors such as glucose level, systemic blood pressure,…”
Get full text

Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program by Zhou, Zien, Jardine, Meg, Perkovic, Vlado, Matthews, David R., Mahaffey, Kenneth W., de Zeeuw, Dick, Fulcher, Greg, Desai, Mehul, Oh, Richard, Simpson, Roger, Watts, Nelson B., Neal, Bruce

“…Aims/hypothesis An increased risk of fracture with canagliflozin vs placebo was reported from the CANagliflozin cardioVascular Assessment Study (CANVAS)…”
Get full text

The End of Dual Therapy with Renin–Angiotensin–Aldosterone System Blockade? by de Zeeuw, Dick

“…Treatment aimed at multiple risk factors and specific markers such as glucose level, blood pressure, body weight, cholesterol levels, and albuminuria has been…”
Get full text

Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program by Matthews, David R., Li, Qiang, Perkovic, Vlado, Mahaffey, Kenneth W., de Zeeuw, Dick, Fulcher, Greg, Desai, Mehul, Hiatt, William R., Nehler, Mark, Fabbrini, Elisa, Kavalam, Mary, Lee, Mary, Neal, Bruce

“…Aims/hypothesis The primary analysis of the Canagliflozin cardioVascular Assessment Study (CANVAS) Program showed canagliflozin to have a beneficial effect on…”
Get full text

Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program by Neuen, Brendon L, Ohkuma, Toshiaki, Neal, Bruce, Matthews, David R, de Zeeuw, Dick, Mahaffey, Kenneth W, Fulcher, Greg, Li, Qiang, Jardine, Meg, Oh, Richard, Heerspink, Hiddo L, Perkovic, Vlado

“…If SGLT2 inhibitors protect the kidneys by reducing albuminuria as hypothesized, people with type 2 diabetes mellitus (T2DM) with higher albuminuria should…”
Get full text

Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS‐R trials by Neal, Bruce, Perkovic, Vlado, Mahaffey, Kenneth W., Fulcher, Greg, Erondu, Ngozi, Desai, Mehul, Shaw, Wayne, Law, Gordon, Walton, Marc K., Rosenthal, Norm, de Zeeuw, Dick, Matthews, David R.

“…Two large cardiovascular outcome trials of canagliflozin, comprising the CANVAS Program, will complete in early 2017: the CANagliflozin cardioVascular…”
Get full text

Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal (CANVAS‐R): A randomized, placebo‐controlled trial by Neal, Bruce, Perkovic, Vlado, Matthews, David R., Mahaffey, Kenneth W., Fulcher, Greg, Meininger, Gary, Erondu, Ngozi, Desai, Mehul, Shaw, Wayne, Vercruysse, Frank, Yee, Jacqueline, Deng, Hsiaowei, de Zeeuw, Dick

“…Aims The primary aim of the CANagliflozin cardioVascular Assessment Study‐Renal (CANVAS‐R) is to determine whether the favourable effects of inhibition of the…”
Get full text

Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes by Molitch, Mark E, Adler, Amanda I, Flyvbjerg, Allan, Nelson, Robert G, So, Wing-Yee, Wanner, Christoph, Kasiske, Bertram L, Wheeler, David C, de Zeeuw, Dick, Mogensen, Carl E

“…The incidence and prevalence of diabetes mellitus (DM) continue to grow markedly throughout the world, due primarily to the increase in type 2 DM (T2DM)…”
Get more information

Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial by Jardine, Meg J, Zhou, Zien, Mahaffey, Kenneth W, Oshima, Megumi, Agarwal, Rajiv, Bakris, George, Bajaj, Harpreet S, Bull, Scott, Cannon, Christopher P, Charytan, David M, de Zeeuw, Dick, Di Tanna, Gian Luca, Greene, Tom, Heerspink, Hiddo J L, Levin, Adeera, Neal, Bruce, Pollock, Carol, Qiu, Rose, Sun, Tao, Wheeler, David C, Zhang, Hong, Zinman, Bernard, Rosenthal, Norman, Perkovic, Vlado

“…Canagliflozin reduced renal and cardiovascular events in people with type 2 diabetes in the CREDENCE trial. We assessed efficacy and safety of canagliflozin by…”
Get full text

Effects of Dietary Sodium and Hydrochlorothiazide on the Antiproteinuric Efficacy of Losartan by VOGT, Liffert, WAANDERS, Femke, BOOMSMA, Frans, DE ZEEUW, Dick, NAVIS, Gerjan

“…There is large interindividual variability in the antiproteinuric response to blockade of the renin-angiotensin-aldosterone system (RAAS). A low-sodium diet or…”
Get full text

Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease by de Zeeuw, Dick, Akizawa, Tadao, Audhya, Paul, Bakris, George L, Chin, Melanie, Christ-Schmidt, Heidi, Goldsberry, Angie, Houser, Mark, Krauth, Melissa, Lambers Heerspink, Hiddo J, McMurray, John J, Meyer, Colin J, Parving, Hans-Henrik, Remuzzi, Giuseppe, Toto, Robert D, Vaziri, Nosratola D, Wanner, Christoph, Wittes, Janet, Wrolstad, Danielle, Chertow, Glenn M

“…Among patients with type 2 diabetes and stage 4 chronic kidney disease, bardoxolone methyl, as compared with placebo, did not reduce the risk of end-stage…”
Get full text